Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Claudia Wagner

Showing results (61-70 of 67) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 67 results.
The Lancet. Oncology|October 11, 2016
IMA901, a multipeptide cancer vaccine, plus sunitinib versus sunitinib alone, as first-line therapy for advanced or metastatic renal cell carcinoma (IMPRINT): a multicentre, open-label, randomised, controlled, phase 3 trialBrian I Rini, Arnulf Stenzl, Romauld Zdrojowy, et al.
Journal for Immunotherapy of Cancer|July 22, 2024
First-in-human dose escalation trial to evaluate the clinical safety and efficacy of an anti-MAGEA1 autologous TCR-transgenic T cell therapy in relapsed and refractory solid tumorsMartin Wermke, Tobias A W Holderried, Jason John Luke, et al.
Nature Medicine|April 9, 2025
Autologous T cell therapy for PRAME<sup>+</sup> advanced solid tumors in HLA-A*02<sup>+</sup> patients: a phase 1 trialMartin Wermke, Dejka M Araujo, Manik Chatterjee, et al.
Science Translational Medicine|August 31, 2022
Quantitative immunopeptidomics reveals a tumor stroma-specific target for T cell therapyGloria B Kim, Jens Fritsche, Sebastian Bunk, et al.
Cancer Immunology Research|May 12, 2023
Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-in-Human Clinical Trial in Patients with Advanced Metastatic CancerApostolia M Tsimberidou, Kerstin Guenther, Borje S Andersson, et al.
Nature|December 21, 2018
Actively personalized vaccination trial for newly diagnosed glioblastomaNorbert Hilf, Sabrina Kuttruff-Coqui, Katrin Frenzel, et al.
Nature|February 9, 2019
Publisher Correction: Actively personalized vaccination trial for newly diagnosed glioblastomaNorbert Hilf, Sabrina Kuttruff-Coqui, Katrin Frenzel, et al.
Pageof 7

Showing results (61-70 of 67) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 67 results.
The Lancet. Oncology|October 11, 2016
IMA901, a multipeptide cancer vaccine, plus sunitinib versus sunitinib alone, as first-line therapy for advanced or metastatic renal cell carcinoma (IMPRINT): a multicentre, open-label, randomised, controlled, phase 3 trialBrian I Rini, Arnulf Stenzl, Romauld Zdrojowy, et al.
Journal for Immunotherapy of Cancer|July 22, 2024
First-in-human dose escalation trial to evaluate the clinical safety and efficacy of an anti-MAGEA1 autologous TCR-transgenic T cell therapy in relapsed and refractory solid tumorsMartin Wermke, Tobias A W Holderried, Jason John Luke, et al.
Nature Medicine|April 9, 2025
Autologous T cell therapy for PRAME<sup>+</sup> advanced solid tumors in HLA-A*02<sup>+</sup> patients: a phase 1 trialMartin Wermke, Dejka M Araujo, Manik Chatterjee, et al.
Science Translational Medicine|August 31, 2022
Quantitative immunopeptidomics reveals a tumor stroma-specific target for T cell therapyGloria B Kim, Jens Fritsche, Sebastian Bunk, et al.
Cancer Immunology Research|May 12, 2023
Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-in-Human Clinical Trial in Patients with Advanced Metastatic CancerApostolia M Tsimberidou, Kerstin Guenther, Borje S Andersson, et al.
Nature|December 21, 2018
Actively personalized vaccination trial for newly diagnosed glioblastomaNorbert Hilf, Sabrina Kuttruff-Coqui, Katrin Frenzel, et al.
Nature|February 9, 2019
Publisher Correction: Actively personalized vaccination trial for newly diagnosed glioblastomaNorbert Hilf, Sabrina Kuttruff-Coqui, Katrin Frenzel, et al.
Pageof 7